Literature DB >> 31111577

Peri-graft porcine-specific CD4+ FoxP3+ regulatory T cells by CD40-CD154 blockade prevented the rejection of porcine islet graft in diabetic mice.

Il-Hee Yoon1, Hyunwoo Chung2,3,4, Hyun-Je Kim2,3,4, Hye-Young Nam2,3, Jun-Seop Shin3,5,6,7, Yong-Hee Kim2,3,4, Chung-Gyu Park2,3,4,5,6,7.   

Abstract

BACKGROUND: Anti-CD154 monoclonal antibody (mAb) treatment has been known to have potential to induce immune tolerance in organ transplantation. Several studies have suggested the involvement of CD4+ regulatory T cells (Treg s) in xeno-immune tolerance. However, the characteristics of Treg s and the mechanisms of their regulatory functions in islet xenotransplantation have not been clearly defined.
METHOD: Adult porcine islet cells were isolated and purified, and were transplanted under the kidney capsule of diabetic C57BL/6J mice with the administration of 0.5 mg/mouse of anti-CD154 mAb on 0, 1, 3, 5, and 7 days post-transplantation (DPT). The graft survival was monitored by blood glucose level. The islet graft and recipients' cells were analyzed by immunohistochemistry (IHC), flow cytometry, enzyme-linked immunosorbent spot (ELISPOT) assay, and mixed-lymphocyte reaction.
RESULTS: Short-term anti-CD154 mAb monotherapy enabled the porcine islet graft to survive indefinitely in diabetic mice (n = 18). Immunohistochemical staining showed significantly higher ratio of CD4+ Foxp3+ Treg s in the peri-graft site, but not in the spleen and kidney-draining lymph node of the recipient mice. Depletion of Treg s evoked graft rejection, and adoptive transfer of Treg s from anti-CD154 mAb-treated recipients provided protection to the graft from rejection. These Treg s showed more potent suppressive capacity than those from the untreated control and were found to be porcine antigen-specific.
CONCLUSIONS: In this study, we showed that anti-CD154 mAb monotherapy resulted in indefinite porcine islet graft survival in mice. The porcine-specific CD4+ Foxp3+ Treg s in the peri-graft site played the critical role in the protection of islet graft from rejection, which suggests a prospective immunosuppressive strategy for islet xenotransplantation.
© 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  CD154; peri-graft site; porcine islet; regulatory T cell; xenotransplantation

Year:  2019        PMID: 31111577     DOI: 10.1111/xen.12533

Source DB:  PubMed          Journal:  Xenotransplantation        ISSN: 0908-665X            Impact factor:   3.907


  6 in total

1.  CD4+ /CD8+ T-cell ratio correlates with the graft fate in pig-to-non-human primate islet xenotransplantation.

Authors:  Hyunwoo Chung; Hyun-Je Kim; Jung-Sik Kim; Il-Hee Yoon; Byoung-Hoon Min; Jun-Seop Shin; Jong-Min Kim; Won-Woo Lee; Chung-Gyu Park
Journal:  Xenotransplantation       Date:  2019-10-23       Impact factor: 3.907

Review 2.  Tregs and Mixed Chimerism as Approaches for Tolerance Induction in Islet Transplantation.

Authors:  Shiva Pathak; Everett H Meyer
Journal:  Front Immunol       Date:  2021-01-29       Impact factor: 7.561

Review 3.  Current status of xenotransplantation research and the strategies for preventing xenograft rejection.

Authors:  Qiao Zhou; Ting Li; Kaiwen Wang; Qi Zhang; Zhuowen Geng; Shaoping Deng; Chunming Cheng; Yi Wang
Journal:  Front Immunol       Date:  2022-07-28       Impact factor: 8.786

Review 4.  Cellular Immune Responses in Islet Xenograft Rejection.

Authors:  Min Hu; Wayne J Hawthorne; Shounan Yi; Philip J O'Connell
Journal:  Front Immunol       Date:  2022-07-07       Impact factor: 8.786

Review 5.  Progress towards xenogenic tolerance.

Authors:  Erin M Duggan; Adam Griesemer
Journal:  Curr Opin Organ Transplant       Date:  2020-10       Impact factor: 2.269

6.  Neonatal Pig Sertoli Cells Survive Xenotransplantation by Creating an Immune Modulatory Environment Involving CD4 and CD8 Regulatory T Cells.

Authors:  Gurvinder Kaur; Kandis Wright; Payal Mital; Taylor Hibler; Jonathan M Miranda; Lea Ann Thompson; Katelyn Halley; Jannette M Dufour
Journal:  Cell Transplant       Date:  2020 Jan-Dec       Impact factor: 4.064

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.